Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | LIPE | Q05469 | 4/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6103199 | 0.94 | TRPV1 (0.48) | TRPV1FAAHTRPA1HIF1AEPAS1 | |
| SCHEMBL5714276 | 0.91 | LIPE (0.46) | TRPV1FAAHTRPA1HIF1AEPAS1 | |
| SCHEMBL6102857 | 0.90 | HIF1A (0.59) | TRPV1FAAHTRPA1HIF1AEPAS1 | |
| SCHEMBL5714206 | 0.86 | LIPE (0.63) | FAAHLIPEBCHE | |
| SCHEMBL5714459 | 0.86 | LIPE (0.45) | TRPV1FAAHTRPA1HIF1AEPAS1 | |
| SCHEMBL5714519 | 0.84 | SLC6A5 (0.49) | TRPV1FAAHTRPA1HIF1AEPAS1 | |
| SCHEMBL5714638 | 0.83 | TP53 (0.48) | LTA4HTHRB | |
| SCHEMBL5715083 | 0.83 | TRPV1 (0.52) | TRPV1TRPA1LIPETHRB | |
| SCHEMBL5714790 | 0.82 | FAAH (0.43) | TRPV1FAAHTRPA1HIF1AEPAS1 | |
| SCHEMBL5715229 | 0.82 | THRB (0.52) | LTA4HTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | LIPE, PNLIP, LPL | TRPV1 1597/4885FAAH 219/4885TRPA1 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.